Gissette Reyes-Soffer, Anastasiya Matveyenko, James Lignos, Nelsa Matienzo, Leinys S Santos Baez, Antonio Hernandez-One, Lau Yung, Renu Nandakumar, Sasha A Singh, Masanori Aikawa, Richard George, Henry N Ginsberg
BACKGROUND: LCAT (lecithin cholesterol acyl transferase) catalyzes the conversion of unesterified, or free cholesterol, to cholesteryl ester, which moves from the surface of HDL (high-density lipoprotein) into the neutral lipid core. As this iterative process continues, nascent lipid-poor HDL is converted to a series of larger, spherical cholesteryl ester-enriched HDL particles that can be cleared by the liver in a process that has been termed reverse cholesterol transport. METHODS: We conducted a randomized, placebocontrolled, crossover study in 5 volunteers with atherosclerotic cardiovascular disease, to examine the effects of an acute increase of recombinant human (rh) LCAT via intravenous administration (300-mg loading dose followed by 150 mg at 48 hours) on the in vivo metabolism of HDL APO (apolipoprotein)A1 and APOA2, and the APOB100-lipoproteins, very low density, intermediate density, and low-density lipoproteins...
May 2, 2024: Arteriosclerosis, Thrombosis, and Vascular Biology